AI+平台经济：恒生科技指数ETF（513180） 网罗港股消费核心资产：港股消费ETF（513230） 全球医药全产业链代表：恒生医药ETF（159892） 汇集中国AI科技概念公司：恒生互联网ETF（513330） （文章来源：每日经济新闻） 5月19日早盘，港股三大指数集体低开，恒生指数跌0.81%，报23156.27点，恒生科指跌1.02%，国企指 数跌0.82%。盘面上，科网股普遍下跌，黄金股普涨，生物医药股分化。相关ETF方面，恒生国企ETF （159850）、恒生ETF（159920）、港股消费ETF（513230）均小幅微跌，持续打开低位布局窗口。 5月16日，恒生指数公司公布季检结果，恒生指数调入美的集团、中通快递，成分股数目将由83只增加 至85只。恒生沪深港通中国企业指数成分股没有变动，成分股数目维持80只。恒生科技指数调入比亚迪 股份，剔除阅文集团，成分股维持30只。恒生生物科技指数将纳入同源康医药-B、康基医疗，剔除康宁 杰瑞制药-B、荣昌生物，成分股维持50只。恒生综合指数将纳入布鲁可、古茗以及蜜雪冰城，成分股由 502只增加至505只。 国泰海通证券表示，复盘历次港股占优行情，不 ...

·我国城市规划"全面体检"套餐出台城市体检将逐步与供地计划等挂钩 ·上市公司重大资产重组新规落地：首次建立分期支付机制首次引入私募基金"反向挂钩"安排 ·穆迪下调美国主权信用评级从Aaa下调至Aa1 ·2025版《国土空间规划城市体检评估规程》5月16日正式发布。这一新版城市"全面体检"套餐更突出以人民为中心，进一步强化规划适应性。增设"城区范 围及周边20公里农用地面积"指标，引导城郊加强"米袋子""菜篮子"建设；增设"水源地数量"指标，推动城市实现多水源保障；专门增加老旧燃气管网改造 进度及管道安全距离控制、电动自行车停车场所空间保障等监测评估；更加关注人民群众的实际感受，"15分钟社区生活圈"评估提级为各城市必选动作；中 小学、养老设施、文体设施、卫生服务设施、菜市场和足球场地等步行5分钟或15分钟覆盖情况都要体检。今年开始，城市体检将逐步与供地计划等挂钩。 （新华社） ·16日，中国证监会正式对外公布实施修订后的《上市公司重大资产重组管理办法》。修订后的重组办法创多个"首次"：首次建立简易审核程序；首次调整 发行股份购买资产的监管要求；首次建立分期支付机制；首次引入私募基金"反向挂钩"安排。（新华社） ...

港股重大调整 5月16日，恒生指数公司在官网公布了截至2025年3月31日的恒生指数系列检讨结果，所有调整将于2025年6月6 日（星期五）收市后实施，并于2025年6月9日（星期一）生效。 根据上述季度检讨结果： 恒生指数调入美的集团（0300.HK）、中通快递（02057.HK），成份股数量将由83只增加至85只。 恒生中国企业指数（"国企指数"）保持不变，成份股数量仍为50只。 恒生科技指数调入比亚迪股份（01211.HK），剔除阅文集团（00772.HK），成份股数量维持30只。 香港恒生综合指数将纳入布鲁可(00325.HK)、古茗(01364.HK)以及 蜜雪集团(02097.HK)，成份股总数将由 502只增至505只。 港股多个指数即将迎来重大调整。 今日，恒生指数有限公司宣布截至2025年3月31日的恒生指数系列检讨结果，多个指数调整成份股。其中，备 受关注的恒生指数调入美的集团、中通快递，成份股数量将增加至85只；恒生科技指数调入比亚迪股份，剔除 阅文集团，成份股数量维持30只。 回到市场层面，今日，港股市场弱势震荡，三大指数集体收跌。但从周线来看，三大指数持续走强，恒生指数 本周累计上涨 ...

5月16日，根据恒生指数公司发布的新闻稿，港股市场将调整多个指数成份股，其中恒生指数成份股将由83只增加至85只。 恒生综合指数成份股数目也有所增加，由502只增加至505只，新加入的3只成份股均为今年上市的股票，其中两只为新茶饮股。 值得注意的是，上述所有变动将于2025年6月6日（星期五）收市后实施，并于2025年6月9日（星期一）起生效。 港股多个指数调整成份股 恒生指数成份股将增至85只 5月16日，恒生指数有限公司(简称"恒生指数公司")宣布了截至2025年3月31日的恒生指数系列季度检讨结果。 其中在港股市场最受关注的指数之一——恒生指数方面，成份股数目将增加，由83只增加至85只，加入美的集团和中通快递—Ｗ，恒生指数成份股的变动亦适用于 恒指港股通指数。 | 代号 | 公司 | 恒指分类指数 | | --- | --- | --- | | 300 | 美的集团股份有限公司 - H 股 | 恒生工商业分类指数 | | 2057 | 中通快递（开曼）有限公司 - W | 恒生工商业分类指数 | 另一个近年比较受关注的指数——恒生科技指数的成份股数目维持30只，加入了比亚迪股份，同时剔除了阅文集团。 ...

Group 1 - The Hang Seng Biotechnology Index will include companies Same Origin Health (02410.HK) and Kangji Medical (09997.HK) [1] - The index will exclude companies CStone Pharmaceuticals-B (09966.HK) and Rongchang Biopharmaceuticals (09995.HK) [1]

中新网湖州5月11日电(胡丰盛张志炜)未来的城市是什么样子？ 是绿意盎然、充满无限可能，消弭钢筋水泥的边界？还是会呼吸的摩天大楼，像森林般吞吐氧气与数 据？ 在湖州，加速跃升的城市能级，正为投资者注入"确定性"强心剂——今年一季度，湖州引进亿元以上项 目212个，同比增加55个；3亿元以上项目144个，同比增加30个；10亿元以上项目34个，同比增加5个。 2025年4月中旬，由蓝箭航天自主研制的天鹊系列发动机在湖州动力制造基地完成第100台下线，这标志 着中国民营商业航天动力系统实现从"单台突破"到"批量制造"的历史性跨越，商业航天动力系统也就此 迈入规模化应用新阶段。 南太湖畔，奉行"长期主义"的浙江湖州通过连续三年高规格的未来大会，给出自己答案。 5月10日下午，总投资691.2亿元的106个项目在湖州未来大会集中签约，涵盖新能源汽车及关键零部 件、半导体及光电、生物医药、高端装备等制造业。湖州市委书记陈浩说，"未来的湖州，产业变革将 加速演进、市场活力将加速迸发、高端要素将加速汇聚、城市能级将加速跃升，成为长三角都市圈的重 要增长极。" 未来共赴欣欣向荣 看一座城市的未来，关键是看潜力、看势头、看变化 ...

Drug Development Pipeline - The company has established a pipeline of 12 candidate drugs since its inception in 2017, including the core product TY-9591 and seven clinical-stage products[7]. - The company is developing multiple candidate drugs in preclinical or early clinical development stages to further enrich its product pipeline[8]. - TY-9591 is currently undergoing critical Phase II trials in China for EGFR-mutant lung cancer brain metastases and Phase III trials for EGFR L858R mutation in advanced or metastatic NSCLC[21]. - The company plans to initiate a Phase II clinical trial for TY-302 in combination with abiraterone for first-line treatment of prostate cancer in the first half of 2025[13]. - The company received IND approval for the Phase II and III clinical trials of TY-9591 in combination with pemetrexed and platinum-based chemotherapy for advanced or metastatic lung cancer[12]. - The company has a diverse pipeline targeting various cancers, including NSCLC, breast cancer, and prostate cancer, with multiple products in different stages of clinical trials[22]. - TY-2136b, an oral ROS1/NTRK inhibitor, has shown good safety in preclinical studies and has received orphan drug designation from the FDA for treating ROS1-positive and NTRK fusion-positive NSCLC[33]. - The company is also preparing for a Phase II trial of TY-9591 in combination with pemetrexed and platinum-based chemotherapy for advanced lung cancer[29]. Financial Performance - The total comprehensive loss for the year ended December 31, 2024, was RMB 387,928 thousand, slightly higher than RMB 383,171 thousand in 2023[11]. - Research and development costs for 2024 were RMB 235,446 thousand, a decrease from RMB 249,252 thousand in 2023[11]. - Revenue increased from RMB 0 in the year ending December 31, 2023, to RMB 107,000 in 2024, mainly driven by increased revenue from research and development services[41]. - Gross profit rose from RMB 0 to RMB 14,000, with a gross margin of 13.1% for the year ending December 31, 2024, attributed to the increase in research and development service revenue[43]. - Administrative expenses surged by 82.7% to RMB 108.3 million in 2024 from RMB 59.3 million in 2023, mainly due to increased listing expenses and operational costs[48]. - Financial costs decreased by 42.4% to RMB 12.8 million in 2024 from RMB 22.2 million in 2023, primarily due to reduced transaction costs related to equity redemption liabilities[49]. - Other income and gains for the year ending December 31, 2024, were RMB 30.5 million, an increase of RMB 5.1 million from RMB 25.4 million in 2023, mainly due to higher government subsidies and bank interest income[44]. Clinical Trial Updates - The key Phase II clinical trial for TY-9591, targeting EGFR mutation lung cancer brain metastasis, completed enrollment of 224 patients in November 2024, with a conditional NDA submission expected in Q2 2025[8]. - The registration Phase III clinical trial for TY-9591, focusing on EGFR L858R mutation lung cancer, completed enrollment of 528 patients in early February 2025, with an NDA submission anticipated in 2026[8]. - TY-302, a CDK4/6 inhibitor, achieved a disease control rate (DCR) of 71.4% in 14 breast cancer patients previously treated with two or more lines of therapy[30]. - The company plans to enter the registration phase for TY-302 in 2026, focusing on its use in breast cancer treatment[30]. - The company has completed five dose escalation studies for TY-2699a, a selective CDK7 inhibitor, and expects to complete the monotherapy escalation phase by the first half of 2025[35]. Market Position and Strategy - The company aims to enhance its market share and brand influence through strengthened marketing and commercialization capabilities[9]. - The company is actively expanding its commercialization team to explore market potential and enhance brand promotion through various academic and industry collaborations[40]. - The company intends to selectively acquire or invest in innovative technologies to strengthen its R&D capabilities and explore potential combination therapy partnerships for TY-9591[69]. - The company is committed to building sales and marketing capabilities through internal efforts and partnerships with external collaborators[69]. - The company aims to explore commercial cooperation opportunities with leading industry peers to accelerate the development of its candidate drugs in key international markets[69]. Governance and Management - The board consists of 11 members, including 4 independent non-executive directors, ensuring compliance with listing rules[176]. - The company has expanded its management team with independent non-executive directors appointed in January 2024, enhancing governance and oversight[86][87]. - The company has purchased liability insurance for directors and senior management to cover potential legal responsibilities[182]. - The board is responsible for strategic decisions, financial oversight, and risk management, ensuring effective governance[181]. - The company has established a committee to oversee the implementation of the employee incentive plan, which includes senior management and key personnel[130]. Risks and Challenges - The company faces significant risks related to the competition in drug development, which may adversely affect its ability to commercialize candidate drugs[106]. - Clinical drug development is a lengthy and costly process, and unexpected difficulties may arise during clinical trials and commercialization[106]. - The company may face significant liabilities related to product liability claims or litigation during drug discovery, development, and commercialization[108]. - The company may not be able to obtain or maintain sufficient patent and other intellectual property protection for its candidate drugs in selected global markets, which could allow third parties to develop and commercialize similar products[111]. - Regulatory approval processes from agencies like the FDA are time-consuming and inherently uncertain, and failure to obtain necessary approvals could severely damage the company's business[113]. Capital and Financing - Cash and bank balances as of December 31, 2024, amounted to RMB 460,463,000, representing a 146.5% increase from RMB 186,830,000 as of December 31, 2023[53]. - The company may require significant additional financing to fund its operations and expansion, and failure to secure such financing could hinder the development and commercialization of its candidate drugs[116]. - The maximum payable amount for technical service fees to Huayu Pharmaceutical under the TY-9591 continuing connected transaction agreement is RMB 4,690,000, with actual transaction amounts being RMB 3,236,000[123]. - The company has entered into a continuing connected transaction agreement with Huayu Pharmaceutical, which will remain effective until the end of 2025[121]. Corporate Social Responsibility - The company made charitable donations amounting to RMB 1.1 million during the reporting period[150]. - The company has not declared any dividends for the year 2024, resulting in no income tax obligations for shareholders[138]. - The company has complied with the relevant provisions of the listing rules regarding related party transactions[126].

在医药行业竞争日益激烈的当下，每一次新药披露临床试验数据都可能意味着现有药物市场格局的改变， 如果一款新药能够通过"头对头"试验胜过现有的重磅药物，其商业前景将不可估量。当中国创新药企 同源 康医药股份有限公司 (2410.HK)宣称，旗下核心管线TY-9591在二期临床的"头对头"试验数据优于已经上市 的"肺癌药王"奥希替尼时，投资者不禁要问：价值千亿的肺癌靶向药市场是否将迎来新的搅局者？ 3月9日，同源康医药发布公告称， TY-9591在关键二期临床中，一线治疗EGFR突变的脑转移肺癌患者的数 据具有统计学显著意义和重大临床获益。值得注意的是，此次披露的二期临床试验的主要研究终点是颅内 客观缓解率(iORR)，在这一指标上，TY-9591对比奥希替尼显示出统计学显著意义和临床意义的明显改善。 "头对头"试验是指采用临床上已使用的治疗药物或方法作为直接对照，在同等试验条件下开展的临床试 验，是两种药物效果的直接对比。 TY-9591是一种第三代EGFR酪氨酸激酶抑制剂（EGFR-TKI），是通过用氘取代奥西替尼中的某些氢原子进 行改良，来减少或减缓奥西替尼的分解，目的是提高其安全性，允许更大的给药剂量，从而 ...

多只纳入港股通股票大涨，有股票盘中飙涨逾70%。 3月10日，A股市场整体走弱，截至中午收盘，上证指数跌0.59%，深证成指跌0.62%，创业板指跌0.81%，不过北证50指数盘中走强。A股市场热点方面，培 育钻石概念明显走强，多股盘中涨停。 港股市场今天上午出现调整，截至发稿，恒生指数盘中跌超2%，恒生科技指数跌超3%。此外，多只纳入港股通的股票大涨，有股票盘中甚至飙涨逾70%。 北证50指数逆势走强 A股市场今天上午整体走弱，主要指数多数下跌，截至中午收盘，上证指数跌0.59%，深证成指跌0.62%，创业板指跌0.81%，科创50指数跌1.51%；不过，北 证50指数表现较强，盘中涨幅一度超过2%。 | 行情 | 资金净流入 | 涨跌分布 | | --- | --- | --- | | 上证指数 | 深证成指 | 北证50 | | 3352.59 | 10776.89 | 1411.72 | | -19.96 -0.59% | -66.84 -0.62% +20.44 +1.47% | | | 科创50 | 创业板指 | 万得全A | | 1090.84 | 2187.53 | 5236.82 | | - ...